Q32 Bio Inc. (QTTB)
NASDAQ: QTTB · IEX Real-Time Price · USD
29.46
+0.50 (1.73%)
At close: Jul 19, 2024, 4:00 PM
29.35
-0.11 (-0.37%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Q32 Bio Revenue
Q32 Bio had revenue of $354.00K in the twelve months ending March 31, 2024. In the year 2023, Q32 Bio had annual revenue of $1.16M.
Revenue (ttm)
$354.00K
Revenue Growth
-93.39%
P/S Ratio
993.83
Revenue / Employee
$9,568
Employees
37
Market Cap
351.81M
Revenue Chart
* The company reports in USD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.16M | -2.05M | -63.97% |
Dec 31, 2022 | 3.21M | -30.76M | -90.56% |
Dec 31, 2021 | 33.97M | 31.27M | 1,157.25% |
Dec 31, 2020 | 2.70M | 1.04M | 62.18% |
Dec 31, 2019 | 1.67M | -3.66M | -68.70% |
Dec 31, 2018 | 5.32M | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ModivCare | 2.78B |
Vanda Pharmaceuticals | 177.60M |
Xeris Biopharma Holdings | 171.36M |
Talkspace | 162.13M |
Cartesian Therapeutics | 25.91M |
uniQure | 19.00M |
AC Immune | 16.82M |
TScan Therapeutics | 14.81M |
QTTB News
- 13 days ago - Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis - PRNewsWire
- 21 days ago - Q32 Bio Joins Russell 3000® Index - PRNewsWire
- 2 months ago - Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer - PRNewsWire
- 4 months ago - Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million - PRNewsWire